888-776-0942 from 8 AM - 10 PM ET
Allergic Rhinitis Market is anticipated to grow owing to factors such as the incoming of novel and emerging potential Allergic Rhinitis treatment therapies and the contribution of pharma giants, companies, and academies working towards Allergic Rhinitis research and development.
LAS VEGAS , Jan. 12, 2022 /PRNewswire/ -- DelveInsight's Allergic Rhinitis Market Insights report proffers a detailed comprehension of Allergic Rhinitis market size by treatment, epidemiology, emerging therapies, Allergic Rhinitis market share of the individual therapies, current and forecasted Allergic Rhinitis market size from 2018 to 2030 segmented into 7MM (the USA , EU5 (the UK, Italy , Spain , France , and Germany ), and Japan ).
Some of the salient features from the Allergic Rhinitis Market Report:
For further information on Market Impact by Therapies, Download Allergic Rhinitis Market sample @ Allergic Rhinitis Market Scenario
Allergic Rhinitis is a condition that occurs when the body (the immune system) overreacts to something in the environment (triggers). It is caused by allergens, which are usually harmless substances but trigger an allergic reaction in some people. When the symptoms occur in late summer or early fall, some people call it hay fever. Those with rhinitis are prone to symptoms such as runny nose, sneezing, congestion, and sinus pressure. In addition, Rhinitis can contribute to other problems such as asthma, sinus or ear conditions, or trouble sleeping.
DelveInsight's analysis indicates that total Allergic Rhinitis prevalent cases in the 7MM countries was 188.40 million cases in 2020 which are expected to grow by 2030, during the forecast period.
Also, as per DelveInsight's estimates, the total number of Allergic Rhinitis prevalence in the United States , was 52.26 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
The Allergic Rhinitis Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Keen to learn how Allergic Rhinitis Epidemiological Trends are going to appear in 2030 for the 7 MM, Download @ Allergic Rhinitis Epidemiological Insights
Currently, the first-line Allergic Rhinitis treatment involves the avoidance of relevant allergens (e.g., house dust mites, molds, pets, pollens) and irritants (e.g., tobacco smoke). The second-generation oral antihistamines (e.g., fexofenadine [Allegra], loratadine [Claritin], cetirizine [Reactine], etc.) are the first-line pharmacological treatments recommended for all patients with Allergic Rhinitis. These medications are available with a prescription or over-the-counter. They work by blocking the histamine that the body releases during an allergic response. Antihistamines come as pills, liquids, eye drops, nasal sprays, and inhalers. They include Loratadine (Claritin), Cetirizine (Zyrtec), Fexofenadine (Allegra), Levocetirizine (Xyzal), etc. Antihistamines can cause drowsiness.
Allergic Rhinitis therapies under development are focused on novel approaches to treat/improve the diseased conditions. Among the Allergic Rhinitis emerging therapies, Regeneron's REGN5713-5714-5715 and REGN 1908-1909 and Inmunotek's MM09 and MG01 appear to be the only drugs that have the potential to transform the Allergic Rhinitis market owing to impressive clinical data. REGN1908-1909, developed by Regeneron Pharmaceuticals, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for the treatment of cat allergy. REGN5713-5714-5715 (Regeneron Pharmaceuticals) is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Betv1, which is the main allergen responsible for birch pollen allergies. Birch allergy can trigger reactions such as Allergic Rhinitis and Asthma.
Among the most anticipated Allergic Rhinitis pipeline therapies is MG56 being developed by Inmunotek for Allergic Rhinitis treatment caused by grass pollens. MG56 contains a mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of MTU(Mannosylated Therapeutic Units)/ml subcutaneous or sublingual. Currently, it is being investigated in Phase II clinical trial. MG01 is another pipeline of Allergic Rhinitis therapy from Inmunotek that constitutes grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne, and Dactylis glomerata). Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde.
Discover more about therapy set to grab substantial Allergic Rhinitis market share @ Allergic Rhinitis Market Landscape
Allergic Rhinitis Pipeline Therapies and Key Companies
To know about more pipeline therapies under different development phases visit @ Allergic Rhinitis Pipeline Analysis, Clinical Trials, and Emerging Therapies
Many pharma giants, companies and academias are working to assess challenges and seek opportunities that could influence Allergic Rhinitis R&D, thus producing many potential therapies focused on novel approaches to treat Allergic Rhinitis. These novel and emerging therapies will significantly impact the Allergic Rhinitis market. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Allergic Rhinitis. In addition to that environmental factors play an important role in the development and exacerbation of Allergic Rhinitis. Due to the increasing pollutants in the environment, the market of Allergic Rhinitis is expected to increase in the forecast period.
On the contrary, the market dominance of over-the-counter and generic medicines in the Allergic Rhinitis space can be observed as a possible hurdle for the Allergic Rhinitis market to a very high extent. Other drawbacks include the slow uptake of immunotherapies, secondary as well as late diagnosis of Allergic Rhinitis, and the high economic burden that may all hinder the Allergic Rhinitis market.
Know which therapy is expected to score the touchdown first @ Allergic Rhinitis Market Landscape and Forecast
Scope of the Allergic Rhinitis Market Report
Discover more about the future market share of Allergic Rhinitis treatment therapies @ Allergic Rhinitis Market Forecast
Allergic Rhinitis Market Overview at a Glance
Executive Summary of Allergic Rhinitis
Allergic Rhinitis Epidemiology and Market Methodology
Allergic Rhinitis: Disease Background and Overview
Allergic Rhinitis Epidemiology and Patient Population
Key Endpoints in Allergic Rhinitis Clinical Trials
Allergic Rhinitis: 7 Major Market Analysis
For further information on Market Impact by Therapies @ Allergic Rhinitis Market Landscape
Get in touch with our Business executive @ Allergic Rhinitis Market Analysis
DelveInsight's, " Allergic Rhinitis Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Allergic Rhinitis companies involved such as Abdi Ibrahim Pharmaceutical, Allergy Therapeutics, Regeneron Pharmaceuticals, Laboratorios LETI, ALK-Abello, Advagene Biopharma, CSPC ZhongQi Pharmaceutical Technology, Array BioPharma, Immunotek and many others.
DelveInsight's ' Allergic Rhinitis Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Allergic Rhinitis epidemiology in the 7MM, i.e., the United States , EU5 (Germany , France , Italy , Spain , and the United Kingdom ), and Japan .
DelveInsight's " Seasonal Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Seasonal Allergic Rhinitis, historical and forecasted epidemiology, as well as the Seasonal Allergic Rhinitis market trends, market drivers, market barriers and key Seasonal Allergic Rhinitis companies, involved such as Regeneron Pharmaceuticals, AOBiome, Emergo Therapeutics, Inmunotek, Novartis Pharmaceuticals, ALK-Abello, Torii Pharmaceutical and Stallergenes Greer
DelveInsight's, " Peanut Allergy Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Peanut Allergy companies involved such as DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L, Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, and others.
DelveInsight's ' Peanut Allergy Market Insights, Epidemiology, and Market Forecast – 2030' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key Peanut Allergy companies involved such as Nestle Health Science, DBV Technologies, Regeneron, Sanofi, Camallergy, Vedanta Biosciences, Alladapt Immunotherapeutics, InnoUp Farma, COUR Pharmaceuticals, Novartis, Genentech, and many others.
DelveInsight's, " Egg Allergy Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Egg Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Egg Allergy companies involved such as Aimmune Therapeutics, DBV Technologies, ASIT Biotech, and others.
DelveInsight's " Egg Allergy Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical and forecasted Egg Allergy epidemiology in the 7MM, i.e., the United States , EU5 (Germany , Spain , Italy , France , and the United Kingdom ), and Japan .
DelveInsight's ' Food Allergy Market Insights, Epidemiology, and Market Forecast—2030' report delivers an in-depth understanding of the Food Allergy (FA), historical and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key Food Allergy companies involved such as Aimmune Therapeutics, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L, COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Aimmune Therapeutics, Regeneron Pharmaceuticals, Genentech, Camallergy, Novartis Pharmaceuticals, and others.
Browse Through Our Blog Posts
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us Shruti Thakur [email protected] +1(919)321-6187 www.delveinsight.com
SOURCE DelveInsight Business Research, LLP
More news releases in similar topics
Cision Distribution 888-776-0942 from 8 AM - 9 PM ET